David J. Restrepo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David J. Restrepo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Jorge Forte
Center for Digital Health, Mayo Clinic, Rochester, MN 55905, USA
5 shared publications Daniel Boczar
Division of Plastic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA
5 shared publications- Andrea Sisti
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL 32224, USA
3 shared publications Andrea Sisti
Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, Fla
2 shared publications- Camilo Andrés Díaz-Quintero
Universidad Pontificia Bolivariana, Medellín, Colombia
2 shared publications Giuseppe Nisi
Division of Plastic and Reconstructive Surgery, Department of Medicine, Surgery and Neuroscience, "S. Maria alle Scotte" Hospital, University of Siena, Siena, Italy
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 41 (3) , 289-302
Eficacia de la radiofrecuencia y el argón plasma estándar e híbrido en el esófago de Barrett displásico: estudio multicéntrico con evidencia en el mundo real y análisis por probabilidad inversa (IPTW)
Antecedentes: la erradicación endoscópica del esófago de Barrett displásico (EBD) mediante coagulación con argón plasma (APC), APC híbrido (APCH) o ablación por radiofrecuencia (RFA) es el estándar actual. Sin embargo, la evidencia comparativa robusta y libre de sesgos de confusión es escasa. El objetivo es comparar la eficacia (recurrencia a 24 meses) y seguridad (eventos adversos mayores) de APC, APCH y RFA en una cohorte de vida real, empleando ponderación por probabilidad inversa del tratamiento (IPTW). Metodología: estudio de cohorte retrospectivo y multicéntrico. Se incluyeron pacientes con EBD tratados con las tres modalidades. Los desenlaces principales fueron la recurrencia de displasia y un compuesto de seguridad (sangrado y estenosis). Se aplicó IPTW mediante la regresión logística multinomial para balancear covariables (edad, índice de masa corporal [IMC], Praga, histología y resección previa) evaluando el equilibrio con la diferencia de medias estandarizada (SMD). Resultados: se analizaron 131 pacientes (APC = 48; APCH = 41; RFA = 42). Luego del ajuste por IPTW, se logró un balance óptimo (SMD <0,1). El análisis multivariado no mostró diferencias significativas en la recurrencia a 24 meses (APC frente a RFA: OR: 0,62, IC 95%: 0,11-3,58; APCH frente a RFA: OR: 1,18, IC 95%: 0,20-6,95) ni en eventos adversos (APC frente a RFA: OR: 0,58, IC 95%: 0,11-3,01; APCH frente a RFA: OR: 0,38, IC 95%: 0,06-2,36). La extensión de Barrett (Praga M) fue el único predictor independiente de recurrencia. Conclusión: después de ajustar por factores de confusión, APC, APCH y RFA demuestran eficacia y seguridad comparables en el tratamiento del EBD. La elección terapéutica debe individualizarse según la disponibilidad, costos y experiencia técnica, dado que ninguna modalidad mostró superioridad clínica intrínseca.
- 11 September 2026
- Published by Asociacion Colombiana de Gastroenterologia in Revista Colombiana de Gastroenterología
- Vol. 41 (3) , 289-302
Open AccessEficacia de la radiofrecuencia y el argón plasma estándar e híbrido en el esófago de Barrett displásico: estudio multicéntrico con evidencia en el mundo real y análisis por probabilidad inversa (IPTW)
Antecedentes: la erradicación endoscópica del esófago de Barrett displásico (EBD) mediante coagulación con argón plasma (APC), APC híbrido (APCH) o ablación por radiofrecuencia (RFA) es el estándar actual. Sin embargo, la evidencia comparativa robusta y libre de sesgos de confusión es escasa. El objetivo es comparar la eficacia (recurrencia a 24 meses) y seguridad (eventos adversos mayores) de APC, APCH y RFA en una cohorte de vida real, empleando ponderación por probabilidad inversa del tratamiento (IPTW). Metodología: estudio de cohorte retrospectivo y multicéntrico. Se incluyeron pacientes con EBD tratados con las tres modalidades. Los desenlaces principales fueron la recurrencia de displasia y un compuesto de seguridad (sangrado y estenosis). Se aplicó IPTW mediante la regresión logística multinomial para balancear covariables (edad, índice de masa corporal [IMC], Praga, histología y resección previa) evaluando el equilibrio con la diferencia de medias estandarizada (SMD). Resultados: se analizaron 131 pacientes (APC = 48; APCH = 41; RFA = 42). Luego del ajuste por IPTW, se logró un balance óptimo (SMD <0,1). El análisis multivariado no mostró diferencias significativas en la recurrencia a 24 meses (APC frente a RFA: OR: 0,62, IC 95%: 0,11-3,58; APCH frente a RFA: OR: 1,18, IC 95%: 0,20-6,95) ni en eventos adversos (APC frente a RFA: OR: 0,58, IC 95%: 0,11-3,01; APCH frente a RFA: OR: 0,38, IC 95%: 0,06-2,36). La extensión de Barrett (Praga M) fue el único predictor independiente de recurrencia. Conclusión: después de ajustar por factores de confusión, APC, APCH y RFA demuestran eficacia y seguridad comparables en el tratamiento del EBD. La elección terapéutica debe individualizarse según la disponibilidad, costos y experiencia técnica, dado que ninguna modalidad mostró superioridad clínica intrínseca.
- Open Access
- 26 June 2026
- Published by Sociedad de Gastroenterologia del Peru in Revista de Gastroenterología del Perú
- Vol. 46 (2) , 115-122
Terapia dual vs cuádruple con bismuto en H. pylori recurrente: ensayo aleatorizado multicéntrico
Con el aumento de la resistencia a los antibióticos, el tratamiento de la infección por H. pylori se ha convertido gradualmente en un reto para los médicos. Objetivo: Comparar la eficacia y seguridad de la terapia dual más bismuto (TDB) con la terapia cuádruple con bismuto (TQB) para el tratamiento de H. pylori en pacientes con por lo menos un fallo en la terapia de erradicación previa. El objetivo primario fue la erradicación de H. pylori a las 6 semanas del tratamiento. Materiales y métodos: Ensayo clínico aleatorizado, abierto y de superioridad, que evaluó la erradicación de H. pylori en pacientes con al menos un fracaso terapéutico previo. Los sujetos fueron asignados aleatoriamente a recibir durante 14 días terapia dual con bismuto (TDB: esomeprazol 40mg tres veces al día, amoxicilina 1g tres veces al día y subsalicilato de bismuto 262mg cuatro veces al día) o terapia cuádruple con bismuto (TQB: esomeprazol 40mg tres veces al día, amoxicilina 1g tres veces al día, doxiciclina 100mg dos veces al día y subsalicilato de bismuto 262mg cuatro veces al día). Resultados: Se aleatorizó a un total de 267 de los 283 sujetos; 11 fueron excluidos debido a los criterios de exclusión y 5 rechazaron participar. Las tasas de erradicación según los análisis por intención de tratar y por protocolo fueron del 90,1% (119/131; IC del 95%: 84,7-94,7%) y del 95,8% (113/118; IC del 95%: 90,5-98,2%) para el TDB, y del 78,7% (107/136; IC del 95%: 71,1-84,7%) y del 84,7% (94/111; IC del 95%: 76,8-90,2%) para el TQB. Se confirmó la superioridad del TDB (p=0,001 en ITT; p=0,04 en PP). Se reportaron eventos adversos en el 30,5% (33/131) de los pacientes tratados con TDB y en el 44,1% (60/136) de los pacientes tratados con TQB (p=0,001). Conclusiones: La terapia dual con bismuto es una mejor alternativa a la terapia cuádruple clásica con bismuto para el tratamiento de pacientes con por lo menos una terapia fallida para H. pylori, ya que proporciona una mayor erradicación con una seguridad y un cumplimiento superiores.
- 26 June 2026
- Published by Sociedad de Gastroenterologia del Peru in Revista de Gastroenterología del Perú
- Vol. 46 (2) , 115-122
Open AccessTerapia dual vs cuádruple con bismuto en H. pylori recurrente: ensayo aleatorizado multicéntrico
Con el aumento de la resistencia a los antibióticos, el tratamiento de la infección por H. pylori se ha convertido gradualmente en un reto para los médicos. Objetivo: Comparar la eficacia y seguridad de la terapia dual más bismuto (TDB) con la terapia cuádruple con bismuto (TQB) para el tratamiento de H. pylori en pacientes con por lo menos un fallo en la terapia de erradicación previa. El objetivo primario fue la erradicación de H. pylori a las 6 semanas del tratamiento. Materiales y métodos: Ensayo clínico aleatorizado, abierto y de superioridad, que evaluó la erradicación de H. pylori en pacientes con al menos un fracaso terapéutico previo. Los sujetos fueron asignados aleatoriamente a recibir durante 14 días terapia dual con bismuto (TDB: esomeprazol 40mg tres veces al día, amoxicilina 1g tres veces al día y subsalicilato de bismuto 262mg cuatro veces al día) o terapia cuádruple con bismuto (TQB: esomeprazol 40mg tres veces al día, amoxicilina 1g tres veces al día, doxiciclina 100mg dos veces al día y subsalicilato de bismuto 262mg cuatro veces al día). Resultados: Se aleatorizó a un total de 267 de los 283 sujetos; 11 fueron excluidos debido a los criterios de exclusión y 5 rechazaron participar. Las tasas de erradicación según los análisis por intención de tratar y por protocolo fueron del 90,1% (119/131; IC del 95%: 84,7-94,7%) y del 95,8% (113/118; IC del 95%: 90,5-98,2%) para el TDB, y del 78,7% (107/136; IC del 95%: 71,1-84,7%) y del 84,7% (94/111; IC del 95%: 76,8-90,2%) para el TQB. Se confirmó la superioridad del TDB (p=0,001 en ITT; p=0,04 en PP). Se reportaron eventos adversos en el 30,5% (33/131) de los pacientes tratados con TDB y en el 44,1% (60/136) de los pacientes tratados con TQB (p=0,001). Conclusiones: La terapia dual con bismuto es una mejor alternativa a la terapia cuádruple clásica con bismuto para el tratamiento de pacientes con por lo menos una terapia fallida para H. pylori, ya que proporciona una mayor erradicación con una seguridad y un cumplimiento superiores.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Pediatric vs Adult Colonoscopes' Effectiveness in Obese Patients: The PACE Randomized Clinical Trial
INTRODUCTION: Obesity is highly prevalent among US adults and is linked to a higher risk of colorectal neoplasia, making it essential to optimize colonoscopy for this population. However, comparative data guiding colonoscope selection in obese individuals remain limited. METHODS: A randomized equivalence clinical trial conducted at 2 Cleveland Clinic Florida locations included patients aged 18 years or older with a body mass index of ≥30 kg/m 2 , scheduled for screening or surveillance colonoscopy. The primary outcome was a composite of successful cecal intubation within 10 minutes without the need for scope exchange. Participants were randomly assigned in a 1:1 ratio to slim (pediatric) or adult colonoscopes. RESULTS: A total of 245 participants entered the study protocol between January and September 2025. The primary endpoint was achieved in 94.3% of the slim colonoscope group and 92.6% of the adult colonoscope group, resulting in an unadjusted absolute risk difference of 1.7% (95% CI: −4.3% to 8.2%). This confirms equivalence within the predefined ±10% margin. After adjusting for sex, body mass index, bowel preparation quality, diverticulosis, and surgical history, the adjusted risk difference was 2.6% (95% CI: −4.3% to 8.6%). Secondary outcomes, including insertion time, withdrawal time, overall cecal intubation rate, terminal ileum intubation rate, adenoma detection rate, and use of ancillary maneuvers, were similar between the study groups. DISCUSSION: Among expert endoscopists, slim and adult colonoscopes are equivalent in facilitating nondifficult colonoscopy in obese patients, with a trend toward improved performance using the slim colonoscope.
- 20 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Pediatric vs Adult Colonoscopes' Effectiveness in Obese Patients: The PACE Randomized Clinical Trial
INTRODUCTION: Obesity is highly prevalent among US adults and is linked to a higher risk of colorectal neoplasia, making it essential to optimize colonoscopy for this population. However, comparative data guiding colonoscope selection in obese individuals remain limited. METHODS: A randomized equivalence clinical trial conducted at 2 Cleveland Clinic Florida locations included patients aged 18 years or older with a body mass index of ≥30 kg/m 2 , scheduled for screening or surveillance colonoscopy. The primary outcome was a composite of successful cecal intubation within 10 minutes without the need for scope exchange. Participants were randomly assigned in a 1:1 ratio to slim (pediatric) or adult colonoscopes. RESULTS: A total of 245 participants entered the study protocol between January and September 2025. The primary endpoint was achieved in 94.3% of the slim colonoscope group and 92.6% of the adult colonoscope group, resulting in an unadjusted absolute risk difference of 1.7% (95% CI: −4.3% to 8.2%). This confirms equivalence within the predefined ±10% margin. After adjusting for sex, body mass index, bowel preparation quality, diverticulosis, and surgical history, the adjusted risk difference was 2.6% (95% CI: −4.3% to 8.6%). Secondary outcomes, including insertion time, withdrawal time, overall cecal intubation rate, terminal ileum intubation rate, adenoma detection rate, and use of ancillary maneuvers, were similar between the study groups. DISCUSSION: Among expert endoscopists, slim and adult colonoscopes are equivalent in facilitating nondifficult colonoscopy in obese patients, with a trend toward improved performance using the slim colonoscope.
- 18 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1285-1288
Mildly Elevated Lipase and Subsequent Risk of Acute Pancreatitis and Pancreatic Cancer
INTRODUCTION: Long-term risk of acute pancreatitis (AP) and pancreatic cancer (PC) with mildly elevated lipase (MEL) is not well established. METHODS: Multicenter retrospective cohort study—“MEL” group had MEL without AP; “no MEL” group had abdominal pain but normal lipase, imaging, endoscopy, and labs. Primary outcomes were incidence of AP or PC in MEL vs no MEL after at least 10-year follow-up. RESULTS: 9,447 patients met inclusion criteria (5,851 MEL, 3,596 no MEL). Logistic regression identified MEL as an independent predictor of AP (2.8% vs 1.2%, odds ratio 2.6, P < 0.001) but not PC (0.4% vs 0.3%, odds ratio 0.7, P 0.38). DISCUSSION: MEL was associated with increased long-term AP risk.
- 18 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (5) , 1285-1288
Mildly Elevated Lipase and Subsequent Risk of Acute Pancreatitis and Pancreatic Cancer
INTRODUCTION: Long-term risk of acute pancreatitis (AP) and pancreatic cancer (PC) with mildly elevated lipase (MEL) is not well established. METHODS: Multicenter retrospective cohort study—“MEL” group had MEL without AP; “no MEL” group had abdominal pain but normal lipase, imaging, endoscopy, and labs. Primary outcomes were incidence of AP or PC in MEL vs no MEL after at least 10-year follow-up. RESULTS: 9,447 patients met inclusion criteria (5,851 MEL, 3,596 no MEL). Logistic regression identified MEL as an independent predictor of AP (2.8% vs 1.2%, odds ratio 2.6, P < 0.001) but not PC (0.4% vs 0.3%, odds ratio 0.7, P 0.38). DISCUSSION: MEL was associated with increased long-term AP risk.
- 19 March 2019
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 43 (3) , 878-879
Combined Breast Reduction Augmentation
- 19 March 2019
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 43 (3) , 878-879
Combined Breast Reduction Augmentation
- 1 March 2019
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 143 (3) , 670e-671e
Meaningful Use of Social Media for Prospective Plastic Surgery Residency Candidates
We read with great interest the article entitled “Connecting with the Next Generation: A Medical Student’s Perspective on Social Media Use and Plastic Surgery.”1 The authors discussed how social media could benefit medical students interested in plastic surgery. We would like to add some considerations regarding the perception of international research fellows looking forward to the competitive Plastic Surgery Match process. Social media eliminate communication barriers and allow the future generation of plastic surgeons to seek mentoring and inspiration from senior surgeons. It is very motivational to see their enthusiasm for practicing and teaching the specialty, and we can get insights through their daily activities.3 It is important to remember that, before drawing conclusions on social media, we must seek the appropriate scientific background by reading medical journals. This is especially relevant for those who come from institutions without plastic surgery departments, as outlined by Weber and Khosravani.1 In fact, a recent editorial in Plastic and Reconstructive Surgery pointed out use of a social media profile to communicate and to reach more readers, and we should take advantage of this following the profile @PRSJournal.2 Chandawarkar et al., in a recent publication entitled “Insta-grated Plastic Surgery Residencies: The Rise of Social Media Use by Trainees and Responsible Guidelines for Use,” pointed out that 14 of 61 integrated plastic surgery residency programs have an Instagram account.4 Those who are selecting residency programs could benefit from this recent trend. Posts sharing daily residents’ experiences are useful for learning more about each residency program before the Match application process. To date (August 5, 2018), we found 1009 posts on Instagram using related hashtags (#plasticsurgeryresidency, #plasticsurgeryresidents, and #plasticsurgeryresident). In summary, we believe the next generation of plastic surgeons is living in a unique moment, where they are able to obtain the necessary information and inspiration through social media to construct their careers. To take advantage of this in a meaningful way, it is essential to seek scientific background and follow plastic surgery journals’ social media. We also encourage people, who are willing to apply to the Plastic Surgery Match, to follow plastic surgery residencies and related hashtags on Instagram. The authors have no financial interest to declare in relation to the content of this communication. This study was supported in part by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Andrea Sisti, M.D. David J. Restrepo, M.D. Brian Rinker, M.D. Antonio Jorge Forte, M.D., Ph.D. Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla.
- 1 March 2019
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 143 (3) , 670e-671e
Meaningful Use of Social Media for Prospective Plastic Surgery Residency Candidates
We read with great interest the article entitled “Connecting with the Next Generation: A Medical Student’s Perspective on Social Media Use and Plastic Surgery.”1 The authors discussed how social media could benefit medical students interested in plastic surgery. We would like to add some considerations regarding the perception of international research fellows looking forward to the competitive Plastic Surgery Match process. Social media eliminate communication barriers and allow the future generation of plastic surgeons to seek mentoring and inspiration from senior surgeons. It is very motivational to see their enthusiasm for practicing and teaching the specialty, and we can get insights through their daily activities.3 It is important to remember that, before drawing conclusions on social media, we must seek the appropriate scientific background by reading medical journals. This is especially relevant for those who come from institutions without plastic surgery departments, as outlined by Weber and Khosravani.1 In fact, a recent editorial in Plastic and Reconstructive Surgery pointed out use of a social media profile to communicate and to reach more readers, and we should take advantage of this following the profile @PRSJournal.2 Chandawarkar et al., in a recent publication entitled “Insta-grated Plastic Surgery Residencies: The Rise of Social Media Use by Trainees and Responsible Guidelines for Use,” pointed out that 14 of 61 integrated plastic surgery residency programs have an Instagram account.4 Those who are selecting residency programs could benefit from this recent trend. Posts sharing daily residents’ experiences are useful for learning more about each residency program before the Match application process. To date (August 5, 2018), we found 1009 posts on Instagram using related hashtags (#plasticsurgeryresidency, #plasticsurgeryresidents, and #plasticsurgeryresident). In summary, we believe the next generation of plastic surgeons is living in a unique moment, where they are able to obtain the necessary information and inspiration through social media to construct their careers. To take advantage of this in a meaningful way, it is essential to seek scientific background and follow plastic surgery journals’ social media. We also encourage people, who are willing to apply to the Plastic Surgery Match, to follow plastic surgery residencies and related hashtags on Instagram. The authors have no financial interest to declare in relation to the content of this communication. This study was supported in part by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Andrea Sisti, M.D. David J. Restrepo, M.D. Brian Rinker, M.D. Antonio Jorge Forte, M.D., Ph.D. Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla.
- 1 March 2019
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 143 (3) , 659e
Evaluation of the In Vivo Kinetics and Biostimulatory Effects of Subcutaneously Injected Hyaluronic Acid Filler
We read with great interest the article by Mochizuki et al. entitled “Evaluation of the In Vivo Kinetics and Biostimulatory Effects of Subcutaneously Injected Hyaluronic Acid Filler.”1 This article reports the results of an investigation on changes in volume and histologic features of tissues after subcutaneous injections of hyaluronic acid into the dorsum of rats. It was noted that although, over time, there was flattening of the site of injection, the total volume did not change. In histologic studies, hyaluronic acid filler acted as a scaffold for self-tissue proliferation.1 This occurred by fibroblast migration and proliferation that subsequently induced collagen production, angiogenesis and, ultimately, adipocyte proliferation. In conclusion, this study demonstrated that, even though hyaluronic acid is reabsorbed, the volume remains constant because of cell proliferation within the injected tissues. Although, in human beings, the total volume is only partially maintained, the biological mechanism is the same. We know and we say to our patients that hyaluronic acid is reabsorbed within 6 months from the injection date, but the pleiotropic properties of this substance on the surrounding tissues are often not taken into account. The biochemical and biomechanical characteristics of hyaluronic acid on the tissue into which it is injected are the key to its popularity as a soft-tissue filler.2,3 In our opinion, the multiple effects of hyaluronic acid on the injected tissue must be fully known and should become an integral part of the knowledge of every physician who practices aesthetic medicine. Hyaluronic acid functions as an osmole, attracting and capturing large amounts of water. This is seen in the joint’s lubrication and wound healing process. Hyaluronic acid is also known to act as an antioxidant, and by stretching tissue, it indirectly stimulates neocollagenogenesis.4 Moreover, in 2014, Paliwal et al. had already evaluated the cellular and molecular changes in skin as a secondary effect of cross-linked hyaluronic acid–based filler in a rodent model.5 In this experiment, it was observed that the filler significantly increased the expression levels of collagen types I and II in rat dermal tissue for up to 12 weeks. An increase in dermal elastin was also reported after this treatment. In gene expression analysis, it was confirmed that extracellular matrix production and assembly were transiently up-regulated through gene expression up-regulation.5 It was demonstrated, in this study, that hyaluronic acid filler enhances the production of several extracellular matrix components, including dermal collagen and elastin. In light of these studies and considerations, we think it would be of paramount importance to consider not only the percentage of reabsorption of hyaluronic acid filler, but also the production of new tissue stimulated by hyaluronic acid itself, partially replacing the reabsorbed amount. The authors have no financial interest to declare in relation to the content of this communication. This study was supported in part by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Daniel Boczar, M.D. David J. Restrepo, M.D. Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla. Plastic and Reconstructive Surgery Unit Santa Maria alle Scotte Hospital University of Siena Siena, Italy Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla.
- 1 March 2019
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 143 (3) , 659e
Evaluation of the In Vivo Kinetics and Biostimulatory Effects of Subcutaneously Injected Hyaluronic Acid Filler
We read with great interest the article by Mochizuki et al. entitled “Evaluation of the In Vivo Kinetics and Biostimulatory Effects of Subcutaneously Injected Hyaluronic Acid Filler.”1 This article reports the results of an investigation on changes in volume and histologic features of tissues after subcutaneous injections of hyaluronic acid into the dorsum of rats. It was noted that although, over time, there was flattening of the site of injection, the total volume did not change. In histologic studies, hyaluronic acid filler acted as a scaffold for self-tissue proliferation.1 This occurred by fibroblast migration and proliferation that subsequently induced collagen production, angiogenesis and, ultimately, adipocyte proliferation. In conclusion, this study demonstrated that, even though hyaluronic acid is reabsorbed, the volume remains constant because of cell proliferation within the injected tissues. Although, in human beings, the total volume is only partially maintained, the biological mechanism is the same. We know and we say to our patients that hyaluronic acid is reabsorbed within 6 months from the injection date, but the pleiotropic properties of this substance on the surrounding tissues are often not taken into account. The biochemical and biomechanical characteristics of hyaluronic acid on the tissue into which it is injected are the key to its popularity as a soft-tissue filler.2,3 In our opinion, the multiple effects of hyaluronic acid on the injected tissue must be fully known and should become an integral part of the knowledge of every physician who practices aesthetic medicine. Hyaluronic acid functions as an osmole, attracting and capturing large amounts of water. This is seen in the joint’s lubrication and wound healing process. Hyaluronic acid is also known to act as an antioxidant, and by stretching tissue, it indirectly stimulates neocollagenogenesis.4 Moreover, in 2014, Paliwal et al. had already evaluated the cellular and molecular changes in skin as a secondary effect of cross-linked hyaluronic acid–based filler in a rodent model.5 In this experiment, it was observed that the filler significantly increased the expression levels of collagen types I and II in rat dermal tissue for up to 12 weeks. An increase in dermal elastin was also reported after this treatment. In gene expression analysis, it was confirmed that extracellular matrix production and assembly were transiently up-regulated through gene expression up-regulation.5 It was demonstrated, in this study, that hyaluronic acid filler enhances the production of several extracellular matrix components, including dermal collagen and elastin. In light of these studies and considerations, we think it would be of paramount importance to consider not only the percentage of reabsorption of hyaluronic acid filler, but also the production of new tissue stimulated by hyaluronic acid itself, partially replacing the reabsorbed amount. The authors have no financial interest to declare in relation to the content of this communication. This study was supported in part by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. Daniel Boczar, M.D. David J. Restrepo, M.D. Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla. Plastic and Reconstructive Surgery Unit Santa Maria alle Scotte Hospital University of Siena Siena, Italy Division of Plastic Surgery and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery Mayo Clinic Jacksonville, Fla.
- 1 February 2019
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 82 (2) , 131-132
Brazilian Perspective on Early Integration of Medical Students Interested in Plastic Surgery
- 1 February 2019
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 82 (2) , 131-132
Brazilian Perspective on Early Integration of Medical Students Interested in Plastic Surgery
- 1 January 2019
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 82 (1) , 1
The Meaning of Plastic Surgery
- 1 January 2019
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 82 (1) , 1
The Meaning of Plastic Surgery